Newark Wayne Dialysis Center is a medicare approved dialysis facility center in Newark, New York and it has 14 dialysis stations. It is located in Wayne county at 1120 South Main Street, Newark, NY, 14513. You can reach out to the office of Newark Wayne Dialysis Center at (315) 331-6958. This dialysis clinic is managed and/or owned by Davita. Newark Wayne Dialysis Center has the following ownership type - Profit. It was first certified by medicare in October, 2013. The medicare id for this facility is 332701 and it accepts patients under medicare ESRD program.
| Name | Newark Wayne Dialysis Center |
|---|---|
| Location | 1120 South Main Street, Newark, New York |
| No. of Dialysis Stations | 14 |
| Medicare ID | 332701 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 1120 South Main Street, Newark, New York, 14513 | |
| (315) 331-6958 | |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
| NPI Number | 1215379078 |
| Organization Name | Newark Wayne Dialysis Center |
| Doing Business As | Enchanted Dialysis Llc |
| Address | 1120 S Main St Newark, New York, 14513 |
| Phone Number | (315) 331-6958 |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 22 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 27 |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 36 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 282 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
| Adult patients getting regular peritoneal dialysis at the center | 4 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 30 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Newark Wayne Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 39 |
| Hypercalcemia patient months | 334 |
| Patients with Serumphosphor | 40 |
| Patients with Serumphosphor less than 3.5 mg/dL | 13 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 36 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 31 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 12 |
| Patients with Serumphosphor greater than 7 mg/dL | 9 |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 26 |
| Patient months included in arterial venous fistula and catheter summaries | 224 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 61 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 25 |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 37 |
| Hospitalization Rate in facility | 281.2 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 458.5 |
| Hospitalization Rate: Lower Confidence Limit | 179.2 |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Newark Wayne Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 29.9 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 40.8 |
| Readmission Rate: Lower Confidence Limit | 20.3 |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Newark Wayne Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.69 (As Expected) |
| SIR: Upper Confidence Limit | 4.07 |
| SIR: Lower Confidence Limit | .54 |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Newark Wayne Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 34 |
| Transfusion Rate in facility | 53.7 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 148.9 |
| Transfusion Rate: Lower Confidence Limit | 22 |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Newark Wayne Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 133 |
| Mortality Rate in facility | 10.1 (Better than Expected) |
| Mortality Rate: Upper Confidence Limit | 17 |
| Mortality Rate: Lower Confidence Limit | 5.5 |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago
Fresenius Kidney Care - Newark Location: 305 West Shore Boulevard, Newark, New York, 14513 Phone: (315) 331-2472 |
Newark Wayne Dialysis Center Location: 1120 South Main Street, Newark, New York, 14513 Phone: (315) 331-6958 |
News Archive
A new grant to awarded George Mason University's Center for Social Complexity will allow researchers to examine how climate change may affect humans and societies over the next 100 years.
New research has found that paying greater attention to internal bodily sensations can increase our appreciation of our own bodies.
Vivakor, Inc. announced today that its Board of Directors approved a dividend of shares of common stock of Regeneca International, Inc.. Vivakor previously received the shares from Regeneca in the fourth quarter of 2009 under a license agreement whereby Vivakor exclusively licensed to Regeneca, for the direct to consumer market, distribution rights to RegeneBlend, one of the new cutting-edge nutraceutical formulations developed by Vivakor.
Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.
› Verified 9 days ago